MX2023014984A - Anticuerpos anti-csp. - Google Patents

Anticuerpos anti-csp.

Info

Publication number
MX2023014984A
MX2023014984A MX2023014984A MX2023014984A MX2023014984A MX 2023014984 A MX2023014984 A MX 2023014984A MX 2023014984 A MX2023014984 A MX 2023014984A MX 2023014984 A MX2023014984 A MX 2023014984A MX 2023014984 A MX2023014984 A MX 2023014984A
Authority
MX
Mexico
Prior art keywords
antibodies
csp
methods
csp antibodies
disclosed
Prior art date
Application number
MX2023014984A
Other languages
English (en)
Spanish (es)
Inventor
Wayne Volkmuth
Randal R Ketchem
Daniel Eric Emerling
Shaun M Lippow
Katherine L Williams
Original Assignee
Atreca Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atreca Inc filed Critical Atreca Inc
Publication of MX2023014984A publication Critical patent/MX2023014984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023014984A 2021-06-17 2022-06-16 Anticuerpos anti-csp. MX2023014984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163211820P 2021-06-17 2021-06-17
PCT/US2022/033877 WO2022266383A1 (en) 2021-06-17 2022-06-16 Anti-csp antibodies

Publications (1)

Publication Number Publication Date
MX2023014984A true MX2023014984A (es) 2024-03-12

Family

ID=84526612

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014984A MX2023014984A (es) 2021-06-17 2022-06-16 Anticuerpos anti-csp.

Country Status (9)

Country Link
US (2) US11655290B2 (cg-RX-API-DMAC7.html)
EP (1) EP4355774A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024524895A (cg-RX-API-DMAC7.html)
KR (1) KR20240047964A (cg-RX-API-DMAC7.html)
CN (1) CN117940450A (cg-RX-API-DMAC7.html)
AU (2) AU2022292722B2 (cg-RX-API-DMAC7.html)
IL (1) IL309422A (cg-RX-API-DMAC7.html)
MX (1) MX2023014984A (cg-RX-API-DMAC7.html)
WO (1) WO2022266383A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322413A (en) * 2023-02-03 2025-09-01 Atreca Inc Variants of anti-CSP antibody
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3954643B2 (ja) 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリア原虫由来のCSおよびHBsAG間のハイブリッド蛋白質
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
SG10201900183VA (en) * 2011-04-28 2019-05-30 Univ Leland Stanford Junior Identification of polynucleotides associated with a sample
KR20180029253A (ko) * 2015-07-22 2018-03-20 유레카 쎄라퓨틱스, 인코포레이티드 Psa 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
US11066464B2 (en) * 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
US20220195023A1 (en) 2019-02-19 2022-06-23 Atreca, Inc. Anti-csp antibody variants

Also Published As

Publication number Publication date
AU2022292722A1 (en) 2024-01-04
KR20240047964A (ko) 2024-04-12
US11655290B2 (en) 2023-05-23
EP4355774A4 (en) 2025-05-07
WO2022266383A1 (en) 2022-12-22
US12545723B2 (en) 2026-02-10
AU2022292722B2 (en) 2025-05-22
AU2025220692A1 (en) 2025-09-11
CN117940450A (zh) 2024-04-26
JP2024524895A (ja) 2024-07-09
NZ806561A (en) 2025-06-27
US20230167169A1 (en) 2023-06-01
IL309422A (en) 2024-02-01
EP4355774A1 (en) 2024-04-24
US20230002483A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
MX2023012245A (es) Compuestos, composiciones y metodos para el tratamiento del cancer.
MX2023014154A (es) Anticuerpos anti-ccr8.
PH12023500015A1 (en) Irak degraders and uses thereof
PH12021553018A1 (en) New egfr inhibitors
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
MY194603A (en) Anti-Complement Factor Bb Antibodies And Uses Thereof
WO2023049790A3 (en) Mdm2 degraders and uses thereof
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
PH12022552371A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2020006290A (es) Dinucleotidos ciclicos como agonistas de sting.
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
PH12020500662A1 (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
MX2025006853A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
MX2024014079A (es) Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
MX2023012739A (es) Anticuerpos anti-gitr y usos de estos.